{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:34:41Z","timestamp":1762551281965,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024603","name":"Blue Earth Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024603","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cpet.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:41:35Z","timestamp":1738741295000},"page":"195-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of PET\/CT in Radiation Oncology for Central Nervous System Tumors"],"prefix":"10.1016","volume":"20","author":[{"given":"William G.","family":"Breen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cpet.2025.01.005_bib1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/neuonc\/now058","article-title":"Response Assessment in Neuro-Oncology working group and\u00a0European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas","volume":"18","author":"Albert","year":"2016","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib2","first-page":"826","article-title":"Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors","volume":"4","author":"DeLaPaz","year":"1983","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.005_bib3","first-page":"518","article-title":"Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes","volume":"8","author":"Parent","year":"2021","journal-title":"Neurooncol Pract"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.005_bib4","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint\u00a0EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0","volume":"51","author":"Albert","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/neuonc\/noae067","article-title":"[Ga68] DOTATATE PET\/MRI-guided radiosurgical treatment planning and response assessment in meningiomas","volume":"26","author":"Ivanidze","year":"2024","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2025.01.005_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3174\/ajnr.A7901","article-title":"Cost-effectiveness analysis of (68)Ga-DOTATATE PET\/MRI in radiotherapy planning in patients with intermediate-risk meningioma","volume":"44","author":"Rodriguez","year":"2023","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/neuonc\/noac131","article-title":"Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET\/RANO group","volume":"24","author":"Galldiks","year":"2022","journal-title":"Neuro Oncol"},{"issue":"16","key":"10.1016\/j.cpet.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/j.ejca.2013.06.039","volume":"49","author":"Gorlia","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1215\/S1152851703000620","article-title":"Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis","volume":"6","author":"Lamborn","year":"2004","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cpet.2025.01.005_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/neuonc\/noab196.253","article-title":"Volumetric and dosimetric patterns of failure analysis of a phase ii clinical trial of 18f-dopa-pet directed dose escalated radiotherapy for glioblastoma","volume":"23","author":"Breen","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00193-x","article-title":"Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement","volume":"11","author":"Rosen","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.005_bib12","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2967\/jnumed.110.078592","article-title":"Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas","volume":"51","author":"Fueger","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0360-3016(02)02984-X","article-title":"Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas","volume":"54","author":"Grosu","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.005_bib14","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/jnnp.2003.028480","article-title":"Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study","volume":"75","author":"Miwa","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.005_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/neuonc\/not002","article-title":"Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study","volume":"15","author":"Pafundi","year":"2013","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.005_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2008.04.050","article-title":"Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme","volume":"73","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1227\/01.NEU.0000338949.94496.85","article-title":"Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients","volume":"64","author":"Pirotte","year":"2009","journal-title":"Neurosurgery"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.005_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","article-title":"PET imaging in patients with meningioma-report of the RANO\/PET Group","volume":"19","author":"Galldiks","year":"2017","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.005_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jon.12632","article-title":"Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas","volume":"29","author":"Ivanidze","year":"2019","journal-title":"J\u00a0Neuroimaging"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/neuros\/nyaa333","article-title":"Simpson grade revisited - intraoperative estimation of the extent of resection in meningiomas versus postoperative somatostatin receptor positron emission tomography\/computed tomography and magnetic resonance imaging","volume":"88","author":"Ueberschaer","year":"2020","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.005_bib21","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.210067","article-title":"Dynamic (68)Ga-DOTATATE PET\/MRI in the diagnosis and management of intracranial meningiomas","volume":"4","author":"Ivanidze","year":"2022","journal-title":"Radiol Imaging Cancer"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib22","doi-asserted-by":"crossref","first-page":"9256","DOI":"10.1038\/s41598-022-13467-9","article-title":"Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [(68)Ga]-DOTATATE PET\/MRI analysis in patients with meningioma","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib23","article-title":"[(68)Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas","volume":"3","author":"Mahase","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.cpet.2025.01.005_bib24","article-title":"PET\/MR imaging of somatostatin receptor expression and tumor vascularity in meningioma: implications for pathophysiology and tumor outcomes","volume":"11","author":"Roytman","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.005_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","article-title":"Expression of somatostatin receptor subtypes in human brain tumors","volume":"76","author":"Dutour","year":"1998","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.005_bib26","first-page":"13185","article-title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance","volume":"8","author":"Silva","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.005_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm1700","article-title":"Simultaneous PET-MRI: a new approach for functional and morphological imaging","volume":"14","author":"Judenhofer","year":"2008","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","article-title":"Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET","volume":"65","author":"Milker-Zabel","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.005_bib30","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1097\/RLU.0000000000002183","article-title":"Detection of metastatic meningioma to the liver using 68Ga-DOTA-Octreotate PET\/CT","volume":"43","author":"Villanueva-Meyer","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.005_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ijrobp.2023.10.014","article-title":"A\u00a0prospective registry study of (68)Ga-DOTATATE PET\/CT incorporation into treatment planning of intracranial meningiomas","volume":"118","author":"Perlow","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.005_bib32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ijrobp.2022.04.009","article-title":"(68)Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma","volume":"113","author":"Perlow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib33","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1097\/RLU.0000000000003382","article-title":"Detection of dural metastases before the onset of clinical symptoms by 16alpha-[18F]Fluoro-17beta-Estradiol PET in a patient with estrogen receptor-positive breast cancer","volume":"46","author":"Boers","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2025.01.005_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111711","article-title":"PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer","volume":"180","author":"Yadav","year":"2024","journal-title":"Eur J Radiol"},{"issue":"16_suppl","key":"10.1016\/j.cpet.2025.01.005_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2023.41.16_suppl.2001","article-title":"Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: results from a prospective phase 2 trial","volume":"41","author":"Kotecha","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11060-023-04377-5","article-title":"(18)F-fluciclovine PET\/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study","volume":"163","author":"Tom","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"issue":"12 Suppl 2","key":"10.1016\/j.cpet.2025.01.005_bib37","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/neuonc\/noad188","article-title":"The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases","volume":"26","author":"Mayo","year":"2024","journal-title":"Neuro Oncol"},{"issue":"12 Suppl 2","key":"10.1016\/j.cpet.2025.01.005_bib38","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/neuonc\/noad260","article-title":"Novel radiotherapeutic strategies in the management of brain metastases: challenging the dogma","volume":"26","author":"Palmer","year":"2024","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.005_bib39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","article-title":"Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma","volume":"32","author":"Albano","year":"2018","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11060-017-2686-3","article-title":"18F-FDG PET\/CT in primary brain lymphoma","volume":"136","author":"Albano","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.005_bib41","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1007\/s00259-021-05386-0","article-title":"Prognostic value of [(18)F]FDG PET\/CT in patients with CNS lymphoma receiving ibrutinib-based therapies","volume":"48","author":"Krebs","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.005_bib42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2967\/jnumed.112.108654","article-title":"18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma","volume":"54","author":"Kasenda","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.005_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-010-0182-0","article-title":"Prognostic value of\u00a0pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment","volume":"100","author":"Kawai","year":"2010","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169828","article-title":"Performance of 89Zr-Labeled-Rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"12","author":"Jauw","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41824-024-00189-6","article-title":"(18)F-FACBC and (18)F-FDG PET\/MRI in the evaluation of 3 patients with primary central nervous system lymphoma: a pilot study","volume":"8","author":"Husby","year":"2024","journal-title":"EJNMMI Rep"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib46","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2021.01.033","article-title":"A\u00a0phase 2 study of dose-intensified chemoradiation using biologically based target volume definition in patients with newly diagnosed glioblastoma","volume":"110","author":"Kim","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.005_bib47","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial results of a phase 2 trial of (18)F-dopa PET-guided dose-escalated radiation therapy for glioblastoma","volume":"110","author":"Laack","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.005_bib48","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S1470-2045(24)00585-0","article-title":"Short-course hypofractionated proton beam therapy, incorporating (18)F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial","volume":"25","author":"Vora","year":"2024","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.cpet.2025.01.005_bib49","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/1078-0432.CCR-22-0171","article-title":"Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma","volume":"28","author":"Harat","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.005_bib50","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1215\/S1522851705000529","article-title":"Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas","volume":"8","author":"Shah","year":"2006","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.005_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/neuonc\/nov179","article-title":"Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma","volume":"18","author":"Shiroishi","year":"2016","journal-title":"Neuro Oncol"},{"issue":"18","key":"10.1016\/j.cpet.2025.01.005_bib53","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/jnci\/93.18.1401","article-title":"Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors","volume":"93","author":"Warren","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.005_bib54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1215\/15228517-2005-005","article-title":"Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods","volume":"8","author":"Galanis","year":"2006","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3174\/ajnr.A6358","article-title":"Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques","volume":"41","author":"Leao","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.005_bib56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.adro.2019.08.004","article-title":"Metabolic tumor volume response assessment using (11)C-methionine positron emission tomography identifies glioblastoma tumor subregions that predict progression better than baseline or anatomic magnetic resonance imaging alone","volume":"5","author":"Miller","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2025.01.005_bib58","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2967\/jnumed.111.098590","article-title":"Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI","volume":"53","author":"Galldiks","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.005_bib59","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2025.01.005_bib60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.mri.2011.04.004","article-title":"Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling","volume":"29","author":"Huang","year":"2011","journal-title":"Magn Reson Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.005_bib61","first-page":"901","article-title":"Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue","volume":"21","author":"Sugahara","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.005_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-022-04011-w","article-title":"Initial results of a phase II trial of (18)F-DOPA PET-guided re-irradiation for recurrent high-grade glioma","volume":"158","author":"Breen","year":"2022","journal-title":"J\u00a0Neuro Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.005_bib63","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.cpet.2025.01.005_bib64","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2024.42.16_suppl.2021","article-title":"Re-irradiation in recurrent glioblastoma: PET- or MRI-based? Results of a prospective randomized clinical trial","volume":"42","author":"Popp","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:07Z","timestamp":1762551007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859825000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1556859825000057"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2025.01.005","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of PET\/CT in Radiation Oncology for Central Nervous System Tumors","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}